Return to news

Parse Biosciences Releases Whole Transcriptome Version 2 Chemistry with Marked Performance Enhancements

Newly released Evercode Whole Transcriptome v2 kits have demonstrably improved gene detection and robustness.

SEATTLE, August 30, 2022 –  Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced today a significant performance update of its chemistry for the Evercode™ Whole Transcriptome products. 

With substantial gains in transcript and gene detection alongside a more robust assay, the newly released chemistry for the Evercode™ Whole Transcriptome products improves upon the previous version in performance areas most relevant to researchers. Over 400 labs around the world have already embraced the Parse Biosciences Evercode combinatorial barcoding technology and its unmatched scale and flexibility for single cell RNA-Seq (scRNA-Seq).

“Our Evercode™ products are empowering labs across the world with accessible and scalable single cell sequencing,” said Alex Rosenberg, CEO and cofounder of Parse Biosciences. “With the release of our new Evercode Whole Transcriptome v2 chemistry, we continue to deliver on that promise – providing unmatched performance to single-cell researchers.”

Evercode™ Whole Transcriptome v2 kits provide the following performance updates:

  • Improved Gene and Transcript Detection: Heightened sensitivity provides researchers more meaningful data in the same experiment.
  • More Robust Performance: The chemistry is more consistent between samples providing more predictable results.
  • Unbiased Gene Expression: Results from the assay can be integrated with any previously acquired single-cell results as no bias was introduced.

“We are just beginning to understand what it means for human health when researchers have easy access to scalable, accurate single-cell sequencing,” said Charlie Roco, CTO and cofounder of Parse Biosciences. “This is only the beginning, not only for Parse Biosciences, but for the broader use of single cell sequencing as a whole.”

The new chemistry is available for the entire Whole Transcriptome product line: WT Mini for experiments up to 10,000 cells or nuclei, WT for experiments up to 100,000 cells or nuclei, and the WT Mega for experiments up to 1,000,000 cells or nuclei. Additionally, the Evercode Cell Fixation and Evercode Nuclei Fixation kits have been updated.

Parse is currently taking orders for the latest products with plans to make the first shipments in two weeks.

For additional information about Parse Biosciences’ newest version, visit https://www.parsebiosciences.com/products/evercode-whole-transcriptome

About Parse Biosciences

Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research.

At the core of our company is our pioneering approach for single cell sequencing. Single-cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. At Parse Biosciences, we are providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease.

To learn more, please visit: https://www.parsebiosciences.com

Media Contact:
Gabby Ferguson
gabby@jones-dilworth.com
309-202-0670